Makindo Medical Notes Comprehensive Medical Encyclopedia | Education for Healthcare Professionals

Makindo Medical Notes "One small step for man, one large step for Makindo"
Download all this content in the Apps now Android App and Apple iPhone/Pad App

MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd.

Dementia

About

Anaesthetics and Critical Care

Obstetrics Gynaecology

Oncology

Ophthalmology

Oral Medicine and Dentistry

Statistics and Research

Stroke

Surgery

Toxicology

Trauma and Orthopaedics

Twitter

Urology

People with dementia are particularly vulnerable to abuse and neglect. All health and social care staff who support them should receive training and follow the local multi-agency policy on adult protection.

About Dementia

Dementia is a progressive neurodegenerative syndrome characterized by a significant decline in cognitive functions that interferes with daily functioning.
Memory, language, attention, visuospatial abilities, and executive function are among the domains commonly affected.

Etiology and Pathophysiology

Alzheimer’s Disease (AD): Characterized by amyloid-beta plaques and neurofibrillary tangles, leading to neuronal death. Genetics, particularly the APOE-e4 allele, plays a significant role.
Vascular Dementia (VaD): Caused by cerebrovascular disease, leading to brain ischaemia and infarctions. Risk factors include hypertension, diabetes, and hyperlipidemia.
Lewy Body Dementia (LBD): Presence of Lewy bodies (alpha-synuclein protein deposits) disrupts neurotransmitter function, affecting cognition and motor skills.
Frontotemporal Dementia (FTD): Linked with tau and TDP-43 protein accumulation, causing selective frontal and temporal lobe degeneration. Often presents with behavioral and language impairments.
Mixed Dementia: A combination of AD and VaD, sharing features and pathologies of both types.
Other Causes: Includes alcoholism, infections (e.g., HIV, syphilis), metabolic disorders, and other neurodegenerative diseases (e.g., Huntington’s disease).

Key Clinical Findings

Impairment in memory (especially recent events) is often an early sign, progressing to more global cognitive dysfunction.
Mood disturbances, personality changes, language impairment, and visuospatial difficulties.
Behavioral and psychological symptoms of dementia (BPSD): agitation, aggression, depression, anxiety, psychosis (hallucinations/delusions), and sleep disturbances.
Functional impairments: Difficulties with ADLs (Activities of Daily Living), such as managing finances, driving, and personal care.

Primary Neurodegenerative Diseases

Alzheimer’s disease (50-70%)
Lewy body dementia (15%)
Vascular dementia (10%)
Frontotemporal dementia (5-10%)

Secondary Causes

Infections: HIV, syphilis, tuberculosis, Whipple’s disease
Endocrine: hypothyroidism, Cushing’s, Addison’s
Vitamin deficiencies: thiamine (Wernicke’s), B12, folate
Substance abuse: chronic alcoholism, drug toxicity
Trauma: chronic traumatic encephalopathy (CTE)
Prion diseases: Creutzfeldt-Jakob disease

Clinical Assessment

History: Comprehensive history from the patient and close contacts, including onset, duration, and progression of symptoms.
Mental Status Examination: Orientation, memory (immediate, short-term, long-term), language, executive function, visuospatial skills, mood, and behavior.
Functional Capacity Assessment: Evaluation of Activities of Daily Living (ADLs) and Instrumental Activities of Daily Living (IADLs).

Physical Examination

Neurological Examination: Focus on motor skills, reflexes, coordination, and presence of focal neurological deficits.
Cardiovascular Examination: Screening for atrial fibrillation, murmurs, carotid bruits (important in vascular dementia).
Systemic Signs: Look for signs of systemic disease contributing to dementia (e.g., liver disease, thyroid dysfunction).

Common Diagnostic and Screening Tests

Mini Mental State Examination (MMSE) - Common screening tool assessing orientation, registration, attention, recall, and language.
Montreal Cognitive Assessment (MOCA) - Sensitive to mild cognitive impairment (MCI), evaluates multiple cognitive domains.

Advanced Diagnostic Imaging and Labs

MRI or CT of the Brain: Identifies cortical atrophy, vascular lesions, and specific patterns suggestive of particular dementias (e.g., hippocampal atrophy in AD).
PET Scan: Useful for distinguishing AD from FTD and evaluating brain metabolism.
CSF Analysis: For biomarkers (Aβ42, tau protein) - Typically in research or specialized settings for diagnosing AD.
Genetic Testing: APOE genotyping for AD risk, particularly for early-onset cases or strong family history.

Differential Diagnosis

Depression (pseudodementia)
Delirium
Mild Cognitive Impairment (MCI)
Normal Pressure Hydrocephalus (NPH)
Other psychiatric disorders
Medication side effects or toxicity

Management Strategies

Management of dementia requires a multidisciplinary approach tailored to the type of dementia, severity, and patient-specific needs.

Non-Pharmacological Interventions

Cognitive Stimulation Therapy: Enhances cognitive functioning in mild to moderate dementia.
Behavioral Therapy: Tailored to manage specific symptoms such as agitation or depression.
Support for Caregivers: Respite care, education, support groups to alleviate caregiver burden.
Environmental Modifications: Adjusting the living environment to reduce confusion and promote safety.
Physical Therapy: To maintain mobility and reduce fall risk.
Occupational Therapy: To assist with daily living activities and adaptive strategies.

Pharmacological Management (According to NICE Guidelines)

Dementia Type	Treatment	Additional Information	Evidence Level
Alzheimer's Disease (Mild to Moderate)	Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)	Improves cognition, memory, and attention in early stages.	B
Alzheimer's Disease (Moderate to Severe)	Memantine, often combined with cholinesterase inhibitors	Combination therapy may help slow progression.	B
Lewy Body Dementia	Cholinesterase inhibitors and memantine	Helps manage hallucinations and cognitive symptoms.	A
Vascular Dementia	No specific medications; address vascular risk factors	Treat hypertension, diabetes, and hyperlipidemia.	B
Frontotemporal Dementia	SSRIs may alleviate behavioral symptoms	Cholinesterase inhibitors are generally ineffective and may worsen symptoms.	A (Cholinesterase inhibitors), B (SSRIs)
Mixed Dementia	Combination of treatments based on dominant pathology (e.g., AD and VaD)	Tailored approach targeting both Alzheimer's and vascular components.	B
Dementia with Behavioral Disturbances	Antipsychotic medications (e.g., risperidone, olanzapine) sparingly	Use with caution due to increased risk of cerebrovascular events in elderly patients.	C

Monitoring and Follow-Up

Regular assessments of cognitive function, behavior, and functional status.
Caregiver support and respite options for sustained management.
Adjustment of pharmacotherapy based on response and tolerability, especially in cases of polypharmacy and comorbidities.
Monitoring for adverse effects of medications.
Periodic review of care plans and intervention strategies.

Complications and Prognosis

Complications: Increased risk of falls, infections, malnutrition, neuropsychiatric symptoms, and reduced mobility.
Prognosis: Progressive decline in most types, with life expectancy varying based on type and severity. Average life expectancy post-diagnosis ranges from 3 to 10 years.
End-of-Life Care: Focus on palliative care, managing symptoms, and providing support to families.

Ethical Considerations

Consent and Capacity: Assessing decision-making capacity and ensuring informed consent for treatments.
Autonomy: Respecting the patient's wishes and preferences in care planning.
End-of-Life Decisions: Advanced directives, do-not-resuscitate (DNR) orders, and palliative care options.
Protection from Abuse: Implementing safeguards against physical, emotional, and financial abuse.
Confidentiality: Maintaining patient privacy while coordinating multidisciplinary care.

Latest Research and Emerging Treatments

Immunotherapy: Targeting amyloid-beta and tau proteins in Alzheimer's disease.
Gene Therapy: Exploring genetic modifications to address familial forms of dementia.
Neuroprotective Agents: Developing drugs that protect neurons from degeneration.
Digital Therapeutics: Utilizing technology for cognitive training and monitoring.
Biomarker Discovery: Identifying new biomarkers for early diagnosis and disease progression tracking.
Stem Cell Therapy: Investigating the potential for stem cells to regenerate neuronal tissue.

References

National Institute for Health and Care Excellence (NICE). (2023). Dementia: Assessment, management and support for people living with dementia and their carers. [Guidelines].
Prince, M., et al. (2023). World Alzheimer Report 2023: Dementia. [Publication].
O’Brien, J.T., & Thomas, A. (2023). Vascular dementia. Lancet, 381(9883), 1683-1692.
McKhann, G.M., et al. (2023). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups. Alzheimer's & Dementia, 19(6), 233-244.
Litvan, I., et al. (2023). Diagnostic criteria for Parkinson’s disease dementia and dementia with Lewy bodies. Movement Disorders, 38(8), 1282-1295.

Glossary

ADLs (Activities of Daily Living): Basic self-care tasks such as bathing, dressing, eating, and toileting.
IADLs (Instrumental Activities of Daily Living): More complex activities related to independent living, such as managing finances, transportation, and medication management.
BPSD (Behavioral and Psychological Symptoms of Dementia): A range of non-cognitive disturbances including agitation, depression, anxiety, and psychosis.
APOE-e4 Allele: A variant of the apolipoprotein E gene associated with increased risk of Alzheimer's disease.
CSF (Cerebrospinal Fluid): Fluid surrounding the brain and spinal cord, analyzed for biomarkers in dementia diagnosis.

PLEASE NOTE LEGAL ADVICE: The contents are under continuing development and improvements and may contain errors of omission or fact. Feedback vital and always welcome at drokane at gmail.com. This is not to be used for the assessment, diagnosis or management of patients. It should not be regarded as medical advice. It is only for educational purposes. Please adhere to your local protocols. If you are unwell please seek healthcare advice from your doctor. This does not replace senior or specialist advice. If you do not accept this then please do not use the website. If you need medical advice, please consult a doctor or other appropriate medical professional. If you are a medical professional and you need advice then speak to your senior or colleagues.

Edit